investorscraft@gmail.com

Stock Analysis & ValuationHaleon plc (HLN)

Previous Close
$9.38
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)52.90464
Intrinsic value (DCF)5.11-46
Graham-Dodd Methodn/a
Graham Formula2.10-78

Company Information

Building 5
Weybridge KT13 0NY
United Kingdom
Phone: 44 1932 822000
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
CEO: Brian James McNamara
Full Time Employees: 24561

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

HomeMenuAccount